Today we’re announcing a new study to advance research on lung cancer. While lung cancer research and targeted therapies have provided hope and progress for many, this study aims to learn more about the genetics behind the disease and its causes. Learn more here: https://23and.me/3zVjzEm
About us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
- Website
-
https://www.23andme.com
External link for 23andMe
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Sunnyvale, California
- Type
- Public Company
- Specialties
- genetic research, consumer genetics, direct-to-consumer genetic testing, telehealth, healthcare, wellness, therapeutics, and drug discovery
Locations
-
Primary
223 N Mathilda Ave
Sunnyvale, California 94086, US
-
349 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at 23andMe
Updates
-
Powerful New York Magazine article on genetic testing for Alzheimer’s disease risk. We celebrate giving access to those who want to know their genetic risk. Genetic testing is a choice we believe gives people agency over their health and facilitates personalized prevention as early as possible. #prevention #genetics #alzheimers https://lnkd.in/gbzDyHs6
-
Our latest Breast, Prostate and Colorectal Cancer polygenic risk score (PRS) reports* work together with our other reports on these conditions to provide 23andMe+® Premium members new insights into their genetic likelihood of developing three of the most common cancers. With these reports and more, you can assess your likelihood and take action through personalized next steps. *Breast Cancer report (females only), Prostate Cancer report (males only) and Colorectal Cancer report (certain ethnicities). The 23andMe Breast, Prostate and Colorectal PRS reports are based on genetic model that include data and insights from 23andMe consented research participants and incorporate thousands of genetic variants to describe if a person has a certain likelihood of developing a condition, but does not describe a person’s overall likelihood. The PRS reports do not account for lifestyle or family history and have not been reviewed by the FDA. The PRS reports are not intended to tell you anything about your current state of health, or to be used to make medical decisions or determine any treatment.
-
In early July, President Biden signed into law the National Plan to End Parkinson's Act. Seeing this bipartisan legislation become law is heartening, as it will bolster efforts to find new treatments and ultimately cure Parkinson's. 23andMe launched our Parkinson's Research effort 15 years ago, leveraging our unique research model to aid in the fight against this disease. More than 33,000 people with Parkinson's are now part of our Parkinson's Research community. That community and the millions of 23andMe customers who have consented to participate in our research make this work possible. Together, we've published over two dozen papers. Collaborating with the Michael J. Fox Foundation and the Parkinson's Foundation, among others, we hope to make progress towards our goal of ending Parkinson’s.
-
We’re looking for a Corporate Counsel to join our legal team! In this role, you’ll advise on a broad range of corporate, governance, securities law, commercial, strategic transactions, and other matters. Come join our Gene Pool! https://lnkd.in/gUXMKaYj
Corporate Counsel – 23andMe Careers
23andme.com
-
You know your calendar age, but do you know your biological age? Our new feature analyzes key biomarkers, from blood tests included in 23andMe+ Total Health, that reflect the condition of major body systems and organs. Part of 23andMe+ Total Health. Our new Biological Age feature helps you monitor how your body is aging physiologically so you can change the trajectory of your health. Learn more: https://23and.me/4eHFuyH The information provided in the Biological Age feature is intended for informational use only, has not been reviewed by a clinician, and is not intended to provide medical advice. Talk to a healthcare professional if you have any concerns or before making any major lifestyle changes.
-
We're excited to announce a strategic collaboration with Nightingale Health to offer more services to our subscribers. 23andMe will pilot Nightingale’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products. More below and in our press release here: https://lnkd.in/grn_ty74
23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel Nightingale Health and 23andMe today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale’s Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products. “We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing. Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are enthusiastic about long-term opportunities that combine the power of our technologies.” “This collaboration enables a globally unique feature set for 23andMe’s consumer health services. Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology,” said Teemu Suna, CEO and Founder of Nightingale Health. “This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market.” Read more: https://lnkd.in/eWnVusH4
-
More thoughts on the new era of genetic medicine from our CEO and co-founder Anne Wojcicki last weekend at #AspenHealth. 🧬 #femalefounder #geneticmedicine #preventativehealthcare
-
You know your calendar age, but do you know your biological age? Our new feature analyzes key biomarkers, from blood tests included in 23andMe+ Total Health, that reflect the condition of major body systems and organs. Part of 23andMe+ Total Health. Our new Biological Age feature* helps you monitor how your body is aging physiologically so you can change the trajectory of your health. Learn more: https://lnkd.in/ghfSzUq5 *The information provided in the Biological Age feature is intended for informational use only, has not been reviewed by a clinician, and is not intended to provide medical advice. Talk to a healthcare professional if you have any concerns or before making any major lifestyle changes.
-
“The fact that the LRRK2 G2019S variant is found in North African Arabs, Ashkenazi Jews, Sephardic Jews as well as populations in Latin America and the Caribbean is a story of our shared genetic roots,” said Lucy Norcliffe-Kaufmann, Ph.D., Principal Scientist with 23andMe’s Parkinson’s Disease Research program. Learn more about the study: https://23and.me/3yNCrEG
The Natural History of a Genetic Variant Associated with Parkinson's Disease
blog.23andme.com